The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Paroxetine: A Review
Open accessAbstract
Paroxetine is a potent and selective serotonin reuptake inhibitor (SSRI) with currently approved indications for the treatment of depression, obsessive‐compulsive disorder, panic disorder and social phobia. It is also used in the treatment of generalized anxiety disorder, post traumatic stress disorder, premenstrual dysphoric disorder and chronic headache. Paroxetine, a phenylpiperidine derivative, is the most potent inhibitor of the reuptake of serotonin (5‐hydroxytryptamine, 5‐HT) of all the currently available antidepressants including the class of SSRIs. It is a very weak inhibitor of norepinephrine (NE) uptake but it is still more potent at this site than the other SSRIs. The selectivity of paroxetine, i.e., the ratio of inhibition of uptake of norepinephrine to serotonin (NE/5‐HT) is amongst the highest of the SSRIs. Paroxetine has little affinity for catecholaminergic, dopaminergic or histaminergic systems and by comparison with tricyclic antidepressants (TCAs) has, therefore, has a reduced propensity to cause central and autonomic side effects. Paroxetine exhibits some affinity for the muscarinic cholinergic receptor but much less than the TCAs. In addition, the adaptive changes of somatodendritic (5‐HT 1A) and terminal (5‐HT 1B/1D) autoreceptors observed with paroxetine are different to those observed with TCAs; it also inhibits nitric oxide synthase. It is both a substrate and an inhibitor of cytochrome isoenzyme P450 2D6. Paroxetine is well absorbed orally and undergoes extensive first pass metabolism that is partially saturable. Its metabolites are pharmacologically inactive in vivo.Steady state levels are achieved after 4–14 days and an elimination half‐life of 21 h is consistent with once‐daily dosing. There is wide inter‐individual variation in the pharmacokinetics of paroxetine in adults as well as in the young and the elderly with higher plasma concentrations and slower elimination noted in the latter. Elimination is also reduced in severe renal and hepatic impairment. Serious adverse events are, however, extremely rare even in overdose. In summary, paroxetine is well tolerated and effective in the treatment of both depressive and anxiety disorders across the age range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Depression, Disability Days, and Days Lost From Work in a Prospective Epidemiologic Survey
Broadhead, W. E. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450190056028 · Cited by 1,237
Keller, M. B. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100053010 · Cited by 864
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492
Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. (1992) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1992.tb04134.x · Cited by 469
Comparison of Paroxetine and Nortriptyline in Depressed Patients With Ischemic Heart Disease
Roose, S. P. (1998) · JAMA · doi:10.1001/jama.279.4.287 · Cited by 453
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
Bolden-Watson, C., & Richelson, E. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90194-8 · Cited by 390
The Efficacy of Antidepressant Drugs: A Review of Research (1958 to 1972)
Morris, J. B. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760110083010 · Cited by 353
Dechant, K. L., & Clissold, S. P. (1991) · Drugs · doi:10.2165/00003495-199141020-00007 · Cited by 325
Paroxetine versus Clomipramine in the Treatment of Obsessive–Compulsive Disorder
Zohar, J., Judge, R., & Ocd Paroxetine Study Investigators (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.4.468 · Cited by 272
Cited by
Prescribed drugs containing nitrogen heterocycles: an overview
Heravi, M. M., & Zadsirjan, V. (2020) · RSC Advances · doi:10.1039/d0ra09198g · Cited by 1,194
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Hirschfeld, R. M. A. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0609 · Cited by 661
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
Metadata
- Authors
- Bourin, M., Chue, P., & Guillon, Y.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 7
- Issue
- 1
- Pages
- 25-47
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2074050752
- Cited by
- 408
- References
- 110
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Paroxetine: A Review. https://app.cochat.ai/papers/10.1111/j.1527-3458.2001.tb00189.x
- The paper
- Bourin, M., Chue, P., & Guillon, Y. (2001). Paroxetine: A Review. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2001.tb00189.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.